PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩500 per share · Prices as of the 2026-10-02 close
Solbrain Holdings posted a surge in net income in 2025 driven by a one-off subsidiary divestiture gain, while its core secondary battery materials business swung to operating losses in the second half before recovering in the first half of 2026.
2025 consolidated net income jumped year over year on a divestiture gain, while operating profit fell sharply, creating a gap with core business profitability
After consecutive operating losses in Q3-Q4 2025, the company posted a small profit in Q1 2026 followed by a much larger profit in Q2 2026
Secondary battery electrolyte and lead-tab operations form the core of revenue, supported by US, Hungarian, and Malaysian units serving North American and European battery supply chains
The September 2025 sale of US biosubsidiary ARK Diagnostics generated large cash proceeds, with part of the consideration reinvested as an equity stake in Artemis JV
As a holding company, performance and US Texas plant progress at affiliate Solbrain (semiconductor materials) can influence the value of its equity stake
Solbrain Holdings is a pure holding company established in 2020 when the former Solbrain split into an investment arm (Holdings) and an operating arm (Solbrain), with equity management and dividend, rental, and investment income as its main revenue sources.
The core of consolidated revenue comes from the secondary battery materials segment run by subsidiaries, which produce electrolyte and lead tabs through US unit Soulbrain MI, Hungarian unit Soulbrain HU, and Malaysian unit Soulbrain E&I, supplying global battery makers such as Samsung SDI, LG Energy Solution, and SK On.
The second pillar is the display materials segment, where units including Soulbrain SLD, Soulbrain Optos, and CMDL provide OLED glass scribing processing services for Samsung Display and produce and sell semiconductor inspection equipment.
The third pillar is biohealthcare, holding in-vitro diagnostics and medical AI units such as Pixcell Medical, Jinchem, and Roswell ME; the former core of this segment, US diagnostics firm ARK Diagnostics, was sold in September 2025.
The holding company itself also owns a stake in listed semiconductor materials firm Solbrain (357780) as its largest shareholder, with resulting shared-service and dividend income booked under the holding business segment.
In June 2026, lithium polymer battery electrode maker Solbrain LTK was spun off and newly consolidated as a subsidiary. Overall, the company operates roughly twenty consolidated subsidiaries spanning three distinct business portfolios—secondary battery materials, display, and biohealthcare—under a holding structure.
In terms of competitive positioning, domestic material makers such as Enchem and Cheonbo compete in battery electrolyte, while affiliate Solbrain competes with firms like Dongwon Industries and ENF Technology in semiconductor materials, meaning that the combined competitiveness of subsidiaries and affiliates, rather than the holding company's direct operations, ultimately drives enterprise value.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩169.4B | ₩19.4B | 11.5% |
| 2025Q3 | ₩98.4B | -₩15.4B | −15.6% |
| 2025Q4 | ₩140.2B | -₩18.4B | −13.1% |
| 2026Q1 | ₩176.3B | ₩1.5B | 0.8% |
| 2026Q2 | ₩208.8B | ₩31.9B | 15.3% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩565.1B | ₩73.5B | ₩59.5B | 13.0% | 5.2% | 42.9% |
| 2023 | ₩661.6B | ₩121B | ₩83.4B | 18.3% | 6.7% | 41.2% |
| 2024 | ₩515.4B | ₩85.3B | ₩58.8B | 16.6% | 4.5% | 33.9% |
| 2025 | ₩556.6B | ₩8.9B | ₩495.6B | 1.6% | 28.6% | 36.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
Consolidated revenue in 2025 rose to KRW 556.6 billion from KRW 515.4 billion in 2024, but operating profit shrank sharply to KRW 8.86 billion from KRW 85.3 billion, pulling the operating margin down from 16.6% to 1.6%.
In contrast, net income attributable to owners jumped to KRW 495.6 billion from KRW 58.8 billion in 2024, reflecting a disposal gain from the September 2025 sale of US biosubsidiary ARK Diagnostics, part of which was contributed in kind for a 40% stake in Artemis JV.
On a quarterly basis, operating profit of KRW 19.4 billion on revenue of KRW 169.4 billion in Q2 2025 turned into an operating loss of KRW 15.4 billion on revenue of KRW 98.4 billion in Q3, followed by a further loss of KRW 18.4 billion on revenue of KRW 140.2 billion in Q4—two consecutive quarters of operating losses.
Operating profit then turned positive at KRW 1.49 billion in Q1 2026, before improving markedly to KRW 31.9 billion on revenue of KRW 208.8 billion in Q2 2026.
This quarterly swing appears to reflect a combination of fluctuating demand in the battery electrolyte segment and structural changes from the subsidiary divestiture.
Compared with 2023 (revenue KRW 661.6 billion, operating profit KRW 121.0 billion, margin 18.3%) and 2022 (revenue KRW 565.1 billion, operating profit KRW 73.5 billion, margin 13.0%), margin volatility over the past two years has clearly widened relative to prior periods.
Consolidated equity grew from KRW 1,181.8 billion in 2022 to KRW 1,947.6 billion in 2025, while the debt ratio fell from 42.9% to 36.5% over the same period, indicating an improvement in overall financial stability.
However, operating cash flow in 2025 was KRW 46.6 billion, down from KRW 85.1 billion in 2024 and KRW 99.5 billion in 2023, showing that actual cash generation softened even as reported net income surged.
The secondary battery electrolyte industry went through a period of slowing electric vehicle demand growth—commonly called the chasm—with weak conditions persisting through the second half of 2025, though signs of renewed growth have emerged as demand diversifies into small and mid-size batteries, power tools, and energy storage systems.
In the United States, tightened Foreign Entity of Concern (FEOC) rules have excluded China-linked electrolyte and material suppliers from IRA subsidy eligibility, highlighting the relative position of non-Chinese suppliers such as Soulbrain MI.
Samsung SDI is building joint-venture battery plants in Indiana with Stellantis and GM respectively, and Soulbrain MI is understood to have expanded its Michigan and Indiana production bases to serve this demand.
On the semiconductor materials side, equity affiliate Solbrain (357780) supplies etchants, precursors, and CMP slurry to Samsung Electronics and SK Hynix, with rising material demand tied to expanded 2026 HBM and NAND investment emerging as an industry-wide theme.
However, Solbrain's US Taylor, Texas phosphoric acid plant saw construction delayed for a time due to customer order uncertainty and rising construction costs, before showing signs of resumption in August 2026 with a project plan filing following a Texas Semiconductor Innovation Fund grant secured earlier in 2026.
The display materials segment depends on OLED glass scribing processing volume for Samsung Display, tying its performance to panel maker utilization rates.
The biohealthcare segment has shrunk in scale following the ARK Diagnostics sale, with a reshuffling underway centered on diagnostic device units such as Pixcell Medical.
Overall, holding company results are a composite of three separate cycles—battery materials recovery pace, the semiconductor materials affiliate's US investment progress, and biohealthcare portfolio restructuring—making it difficult to characterize the industry cycle through any single lens.
In its Q3 2025 report, the company stated that the secondary battery segment saw slowing growth due to weaker EV demand but was showing renewed growth centered on small and mid-size batteries, and that it had completed capacity expansion for electrolyte production at its Hungarian and US units in response to EV and ESS market growth.
The first-half 2026 results—a swing to profit in Q1 and a much larger profit in Q2—can be interpreted as partly reflecting these expansion effects and a demand recovery, though no quantitative full-year 2026 guidance from the company was confirmed.
On the capital policy front, the company decided in February 2026 to retire treasury shares while also disclosing a convertible bond issuance for fundraising around the same time.
In June, lithium polymer battery electrode maker Solbrain LTK was spun off and newly consolidated as a subsidiary, extending the company's footprint in the battery value chain from materials into electrodes.
How the large cash pile secured from the ARK Diagnostics sale is redeployed going forward has been flagged as a key variable for enterprise value, with potential uses spanning further M&A, new business investment, or shareholder returns.
Affiliate Solbrain's US Texas phosphoric acid plant, following an August 2026 project plan filing, targets construction starting as early as September and completion by February 2028, and this progress could affect the value of the equity stake held.
However, there have also been reports that some of the plant's originally targeted volume shifted to a competitor, meaning actual utilization and customer wins after completion warrant continued monitoring.
The current share price trades below net asset value per share on an equity basis, placing it in a range assessed at a discount to net assets.
On the earnings side, 2025 net income includes a large one-off disposal gain from a subsidiary sale, so profitability metrics calculated on that basis carry a different character from recurring core earnings power.
On the operating side, the shift from losses in the second half of 2025 to profits in the first half of 2026 points to a directional change that could be read as an early signal of core business profitability recovery.
The company has a history of paying an annual cash dividend, and given its holding company structure, dividend income from subsidiaries and affiliates makes up a meaningful portion of the holding business segment's revenue.
It is also worth considering that holding companies typically trade at a discount to the sum of the value of their subsidiary and affiliate stakes.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
After consecutive operating losses in Q3 and Q4 2025, the company swung to profit in Q1 2026 and saw a much larger improvement in Q2. Revenue also rose sequentially to KRW 208.8 billion in Q2, with both scale and margin improving together.
Whether this recovery stems from normalizing battery demand, the contribution of newly consolidated Solbrain LTK, or cost structure improvements requires confirmation through subsequent disclosures.
The ARK Diagnostics sale generated a large cash balance, and a sizable distributable profit limit gives the company financial capacity to pair this with shareholder returns such as treasury share retirement. The debt ratio fell from 42.9% in 2022 to 36.5% in 2025, while equity rose consistently over the same period. Once reinvestment plans are finalized, there is potential for this to translate into new growth drivers.
US electrolyte producer Soulbrain MI is understood to have served Samsung SDI's Stellantis and GM joint-venture plant volumes through its Michigan and Indiana bases.
Tightened FEOC rules excluding China-linked electrolyte supply from IRA subsidies is a factor that highlights the relative position of non-Chinese suppliers. The structure allows for potential spillover benefits depending on whether Samsung SDI makes further US investments.
The 2025 net income surge was largely driven by the low-repeatability factor of the ARK Diagnostics disposal gain. Operating profit over the same period fell sharply to KRW 8.86 billion, pulling the operating margin down to 1.6%.
The actual pace of core business profitability recovery, excluding the disposal gain, needs to be reconfirmed through future quarterly results.
Slowing EV demand growth was cited as a major factor behind the operating losses in the second half of 2025. After posting losses for two consecutive quarters in Q3 and Q4 2025 before recovering in H1 2026, a renewed slowdown in the EV demand cycle could reproduce similar margin pressure.
How much demand diversification into small and mid-size batteries and ESS actually contributes to results warrants continued monitoring.
Given the holding company structure, the performance and US investment progress of semiconductor materials affiliate Solbrain can affect the value of the equity stake.
Solbrain's Taylor, Texas phosphoric acid plant saw construction delayed for a time due to customer order uncertainty and rising construction costs, with reports that some targeted volume shifted to a competitor.
While an August 2026 project plan filing signals a resumption, the possibility of further delays before completion and startup cannot be ruled out.
Subsidiary portfolio changes have followed one another over the past year, including the ARK Diagnostics sale and the Solbrain LTK consolidation. Part of the sale proceeds was reinvested as an equity stake in Artemis JV rather than fully converted to cash. If portfolio restructuring continues, comparability of consolidated results going forward could be reduced.
The secondary battery segment has been directly affected by the slowdown in EV demand growth, while the display segment is tied to Samsung Display's panel utilization rate. Both segments share exposure to end-market demand cycles that the holding company cannot directly control. If the pace of demand recovery diverges from expectations, earnings volatility could widen again.
A convertible bond issuance was disclosed in February 2026, meaning the possibility of equity dilution upon future conversion cannot be ruled out.
In addition, the holding company's stake in its semiconductor materials affiliate does not amount to full controlling ownership, creating a structural limitation whereby the affiliate's independent decisions are only indirectly reflected in the holding company's results.
Disclosures on changes in the largest shareholder's and related parties' holdings also warrant continued monitoring.
Check whether Q3 2026 results continue the operating profit recovery seen in Q2, and whether revenue growth and margin improvement occur together. As results for this period are not yet disclosed, any figures circulating beforehand should be treated only as preliminary.
Track whether affiliate Solbrain's US Taylor, Texas phosphoric acid plant is built and completed on schedule and whether customer volumes are actually secured. Given a past history of construction delays, progress should be re-verified periodically.
Watch for disclosures on how the large cash pile from the ARK Diagnostics sale is redeployed, whether through M&A, new investment, or shareholder returns. This has been flagged as a factor with significant potential impact on enterprise value.
Check how much newly consolidated Solbrain LTK (lithium polymer battery electrode manufacturing), added in June 2026, actually contributes to consolidated revenue and operating profit.
Solbrain Holdings saw a large increase in net income in 2025 driven by a subsidiary divestiture gain, while operating profit over the same period fell sharply, creating a clear gap between core profitability and the net income figure.
The secondary battery materials segment endured two consecutive quarters of losses in the second half of 2025 before turning profitable in the first half of 2026, showing signs of recovery, though whether this reflects a structural improvement tied to EV demand recovery or a temporary factor requires confirmation through further quarterly results.
Given the holding company structure, the US investment progress and performance of semiconductor materials affiliate Solbrain also affect the value of the equity stake, and that affiliate's Texas plant has shown signs of resuming after a period of delay.
Financially, stability has improved with a lower debt ratio and growing equity, and the large cash balance secured from the ARK Diagnostics sale has been flagged as a variable that could meaningfully affect enterprise value depending on future reinvestment direction.
Capital policy has also unfolded on multiple fronts, with treasury share retirement and a convertible bond issuance occurring around the same period.
Investors will want to track three threads together: the actual pace of core business recovery excluding one-off gains, progress on the affiliate's investment, and the direction of cash reinvestment.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.